PTGS2 and breast cancer: Although reports of the prognostic value of COX-2 vary from study to study, and lead to no consensus, a recent meta-analysis by Xu et al. [28] showed that COX-2 overexpression in breast cancer is associated with poor prognosis as well as larger tumor size and lymph node metastasis.